Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636803 | 0.87 | MAPT (0.48) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL637450 | 0.87 | ALDH1A1 (0.51) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL638378 | 0.87 | ALDH1A1 (0.51) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL637451 | 0.87 | ALDH1A1 (0.51) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL10157792 | 0.87 | ALDH1A1 (0.51) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL13574484 | 0.87 | MAPT (0.48) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL636802 | 0.87 | MAPT (0.48) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL10195517 | 0.85 | BCHE (0.44) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL10194427 | 0.85 | BCHE (0.44) | BCHEGAABCL9CTNNB1HTR2A | |
| SCHEMBL22893118 | 0.83 | BCL9 (0.48) | GAABCL9CTNNB1HTR2APTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003811-B2 | Nitric oxide donor compounds | NICOX S.A. (FR) | 2011-08-23 | — | — | US | disclosed |
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2011-03-31 | — | — | US | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077279-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, AGT | BCHE 2032/4885GAA 4067/4885BCL9 4339/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | BCHE 951/4885GAA 2529/4885BCL9 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.